Pricing Log in Create free account
Saturday 7 November 2026 Export DRMA’s income statement to Excel — free account

Dermata Therapeutics, Inc.

DRMA Healthcare Biotechnology

EPS
+55.4%
Free cash flow
+9.99%

Quarter to June 2026, against a year earlier

0.77 0.01 +1.32%
Market cap
$3.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.00
Sold, $m 0.00
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 1 — — — — — — — — —
Sell — — — — — — 1 — — — — —
Insider Ownership 28.89%

Capital & Financial Ratios $m

Size
Market Cap 3.78
Revenue ttm —
Net income ttm (8.37)
Free cash flow ttm (8.03)
Net debt Q (4.41)
Valuation
P/E 0.00
Forward P/E —
Price / sales 0.00
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.89
Financial health
Current ratio Q 2.81 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (19.53)
Growth
Revenue growth Q —
Operating income growth Q −70.00% (below 0%: shrinking)
EPS, this year +73.41% (at or above 15%: strong)
EPS, next year A +34.10% (at or above 15%: strong)
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A +65.25% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

P/B against its own 10 years 71.14%
10-year low 10-year high
EV/FCF against its own 10 years 11.34%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 7 3 8 4
Receivables — — — —
Inventory — — — 0
Other — — — —
8 4 8 5
2023 2024 2025 Q'26
Payables 1 1 0 1
ST’ Debt — — — —
Other — — — —
2 2 2 2

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 1.10%

EPS $

Mar Jun Sep Dec Year
’26 (0.48) (0.74) — — —
’25 (4.50) (1.66) (1.65) (1.64) (8.16)
’24 (70.46) (41.80) (20.40) (9.15) (80.30)
’23 (340.33) (94.45) (80.96) (66.54) (400.30)
’22 (791.60) (575.71) (479.76) (287.86) (2.09k)
’21 (2.89k) (1.68k) (825.09) 983.66 (5.83k)
’20 (1.78k) (1.03k) (749.88) (497.47) (4.06k)
Fiscal quarters ending in the months shown.

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (3) (2) (1) (8)
’24 (3) (2) (3) (3) (11)
’23 (2) (2) (2) (1) (6)
’22 (3) (2) (3) (2) (9)
’21 (1) (1) (2) (2) (6)
’20 (1) (1) (1) (1) (4)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (3) (2) (1) (8)
’24 (3) (2) (3) (3) (11)
’23 (2) (2) (2) (1) (6)
’22 (3) (2) (3) (2) (9)
’21 (1) (1) (2) (2) (6)
’20 (1) (1) (1) (1) (4)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — 0 1 — +650.0%
Gross margin, % — — — 0.00 0.00 — — — — — — 0.0 pt
EBT — — — (5) (3) (8) (10) (8) (12) (8) (8) +8.2%
EBT margin, % — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
Net income — 0 — (5) (3) (8) (10) (8) (12) (8) (8) n/m
Per share, $
Per share, $ Revenue — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Earnings — — — (5,926.50) (4,062.67) (5,829.08) (2,086.96) (400.30) (80.30) (8.16) (4.51) (66.6%)
Cash flow — — — (4,902.87) (5,035.62) (3,163.00) (1,920.48) (328.66) (72.96) (8.38) (2.00) (65.4%)
Capex — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow — — — (4,902.87) (5,035.62) (3,163.00) (1,920.48) (328.66) (72.96) (8.38) (2.00) (65.4%)
Book value — — — (262.75) (3,972.37) 5,615.06 1,309.11 325.90 10.20 6.72 0.87 n/m
Shares, m — — — 0 0 0 0 0 0 1 2 +224.0%
Valuation, ×
Valuation, × P/E — — — — — — — — — — 0 —
P/S — — — — — — — — — — 0 —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — 0 —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow — — — (4) (4) (6) (9) (6) (11) (8) (8) +12.0%
Capex — — — — — — — — — — — —
Free cash flow — — — (4) (4) (6) (9) (6) (11) (8) (8) +12.0%
Balance, $m
Balance, $m Working capital — — — 0 (3) 10 6 6 2 6 3 +62.1%
Net debt — — — (1) 3 (11) (6) (7) (3) (8) (4) +48.3%
Shareholders’ equity — — — 0 (3) 10 6 6 2 6 3 n/m
Returns, %
Returns, % ROA — — — (457.10) (242.32) (171.14) (103.52) (104.46) (213.46) (132.63) (139.93) +324.5 pt
ROIC — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE — — — 19.58 13.42 134.00 (119.18) (125.96) (310.44) (194.20) (183.89) (213.8) pt
People
People Employees — — — — 7 8 8 8 8 9 — +5.2%
Revenue/emp, $m — — — — 0.00 0.00 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fundamentals updated 26 Oct 2026

Dermata Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OSRH OSR Health, Inc. $4.1M — (loss-making) — −72.20% (below 0%: shrinking) n/m −398.76% (below 0%: shrinking) 27.43% (960.69%) Compare
NCNA NuCana PLC Sponsored ADR $4.0M — (loss-making) — — n/m +55.66% (above 0%: growing) 0.00% 0.00% Compare
PMCB Nuvilex Inc. $4.0M — (loss-making) — −103.94% (below 0%: shrinking) n/m +60.84% (above 0%: growing) 100.00% 0.00% Compare
CELZ Creative Medical Technology Holdings, Inc. $4.0M — (loss-making) — (loss-making) 0.00% n/m −27.05% (below 0%: shrinking) 66.67% 0.00% Compare
DRMA Dermata Therapeutics, Inc. $3.8M — (loss-making) — — n/m +9.99% (above 0%: growing) 0.00% 0.00%
CVKD Cadrenal Therapeutics, Inc. $3.6M — (loss-making) — — n/m +26.24% (above 0%: growing) 0.00% 0.00% Compare
LIMN Liminatus Pharma Inc. $3.5M — (loss-making) — — n/m +89.00% (above 0%: growing) — 0.00% Compare
GRI GRI Bio, Inc. $3.4M — (loss-making) — (loss-making) — n/m +54.33% (above 0%: growing) 0.00% 0.00% Compare
LIPO Lipella Pharmaceuticals Inc. $3.4M — (loss-making) — (loss-making) −36.44% (below 0%: shrinking) n/m −41.79% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $3.8M — — −54.32% — +40.29% 27.43% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 17 April 2026

Ownership

Directors and executive officers, together 21.90%
Gerald T. Proehl 17.30%
Entities Affiliated with Bigger Capital Fund L.P. 9.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Dermata Therapeutics, Inc. (DRMA) Latest News

29 Oct

Impact 4 · · ACCESS Newswire

15 Oct

Impact 3 · · ACCESS Newswire

25 Aug

Impact 4 ·

21 Aug

Impact 4 ·

5 Aug

Impact 4 ·

13 May

Impact 3 · · ACCESS Newswire

2 Apr

Impact 3 · · ACCESS Newswire

26 Mar

Impact 3 · · ACCESS Newswire

5 Mar

Impact 4 · · ACCESS Newswire

20 Jan

Impact 4 · · ACCESS Newswire

30 Dec

Impact 3 · · Associated Press Finance

29 Dec

Impact 3 · · ACCESS Newswire

24 Dec

Impact 3 · · Associated Press Finance
Impact 3 · · ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires

4 Dec

Impact 4 · · ACCESS NewswireGuruFocus.comGuruFocus.comInsider MonkeyGuruFocus.comMotley FoolMotley FoolGuruFocus.com

14 Nov

Impact 3 · · ACCESS Newswire

2 Oct

Impact 4 · · ACCESS Newswire

17 Sep

Impact 3 · · ACCESS NewswireACCESS NewswireGlobeNewswire

16 Sep

Impact 3 · · GlobeNewswire

10 Sep

Impact 4 · · ACCESS Newswire

13 Aug

Impact 3 · · ACCESS Newswire

8 Jul

Impact 4 ·

14 May

Impact 4 · · ACCESS Newswire

15 Apr

Impact 4 · · ACCESS Newswire

27 Mar

Impact 4 · · ACCESS Newswire
Impact 4 · · PR Newswire

17 Mar

Impact 3 ·

4 Mar

Impact 4 · · PR Newswire

25 Feb

Impact 4 · · ACCESS Newswire

29 Jan

Impact 4 ·
stockrow.com/DRMA · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com